Malvern, PA, United States

Time filter

Source Type

Patent
Walter, Eliza Hall Institute of Medical Research and TetraLogic Pharmaceuticals | Date: 2014-06-25

The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.


Patent
TetraLogic Pharmaceuticals | Date: 2013-06-06

The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.


Patent
TetraLogic Pharmaceuticals | Date: 2014-07-21

Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language


Patent
TetraLogic Pharmaceuticals | Date: 2014-04-07

A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes.


Patent
TetraLogic Pharmaceuticals | Date: 2013-06-25

Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language


Patent
TetraLogic Pharmaceuticals | Date: 2013-06-25

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPB (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K_(d )of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.


Patent
TetraLogic Pharmaceuticals | Date: 2015-01-28

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.


Patent
TetraLogic Pharmaceuticals | Date: 2013-11-08

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.


Patent
TetraLogic Pharmaceuticals | Date: 2013-08-01

A combination therapy comprising administration of a Smac mimetic and GM-CSF.


Patent
TetraLogic Pharmaceuticals | Date: 2014-07-16

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K_(d )of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.

Loading TetraLogic Pharmaceuticals collaborators
Loading TetraLogic Pharmaceuticals collaborators